Adoptive transfer of chimeric antigen receptor (CAR) T lymphocytes is a powerful technology
that has revolutionized the way we conceive immunotherapy. The impressive clinical results …

Acute Myeloid Leukemia (AML) is an aggressive myeloid malignancy associated with high
mortality rates (less than 30% 5-year survival). Despite advances in our understanding of the …

Simple Summary Chimeric antigen receptor (CAR) therapy has increased treatment options
for many patients who have failed standard chemotherapy. So far, CAR therapy has been …

Chimeric antigen receptor (CAR) T-cell therapy has been widely successful in the treatment
of B-cell malignancies, including B-cell lymphoma, mantle cell lymphoma, and multiple …

The most common kind of acute leukemia in adults is acute myeloid leukemia (AML), which
is often treated with induction chemotherapy regimens followed by consolidation or …

High-Grade Gliomas (HGG) are among the deadliest malignant tumors of central nervous
system (CNS) in pediatrics. Despite aggressive multimodal treatment-including surgical …

Following the success of immunotherapies such as chimeric antigen receptor transgenic T-
cell (CAR-T) therapy, bispecific T-cell engager therapy, and immune checkpoint inhibitors in …

The quality of chimeric antigen receptor (CAR)-T cell products, namely, memory and
exhaustion markers, affects the long-term functionality of CAR-T cells. We previously …

Since the introduction of the use of chimeric antigen receptor T-cell therapy (CAR-T therapy)
dramatically changed the therapeutic strategy for B cell tumors, various CAR-T cell products …

Background aims Chimeric antigen receptor T (CAR-T) cells are a remarkably efficacious,
highly promising and rapidly evolving strategy in the field of immuno-oncology. The …